I see a lot of people pointing to the numerical superiority of support from ODAC as a marker for future success.
and yes, numerically, the support is strong. But in substance, IMO, that one dissenting voice represents big problems for MSB. It is saying "BIg pharma does not approve" and that they will likely try to muscle MSB out.
That's a big enemy to have.
Now obviously the FDA will look at the facts of the treatment. But it'd be foolish to believe Big Pharma would not be able to exacerbate any niggling suspicions or worries the FDA might have about the treatment. And that might just be enough to sway a conservative FDA decision.
Cell Therapy News/Articles, page-6412
-
- There are more pages in this discussion • 11,834 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |